The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052.
Mary O'Brien
No relevant relationships to disclose
Rabab Mohamed Gaafar
No relevant relationships to disclose
Sanjaykumar Popat
No relevant relationships to disclose
Francesco Grossi
No relevant relationships to disclose
Allan Price
No relevant relationships to disclose
Denis Charles Talbot
No relevant relationships to disclose
Tanja Cufer
No relevant relationships to disclose
Christian H.H Ottensmeier
No relevant relationships to disclose
Sarah Danson
No relevant relationships to disclose
Athanasios G. Pallis
No relevant relationships to disclose
Baktiar Hasan
No relevant relationships to disclose
Jan P. Van Meerbeeck
No relevant relationships to disclose
Paul Baas
No relevant relationships to disclose